[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
News From the Centers for Disease Control and Prevention
September 22/29, 2015

Spreading US Macrolide Resistance

JAMA. 2015;314(12):1218. doi:10.1001/jama.2015.11206

Resistance to macrolides—the preferred treatment for Mycoplasma pneumoniae infections in children—may be more widespread in the United States than previous research had indicated.

In a recent study using molecular and phenotypic techniques at 6 US medical centers, investigators detected macrolide resistance in 13.2% of 91 M pneumoniae–positive specimens, most of which were obtained from patients 18 years or younger. Among the 80 respiratory specimens that included co-infection data, 32.5% had a viral pathogen in addition to M pneumoniae (Zheng X et al. Emerg Infect Dis. 2015;21[8]:1470-1472).